Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study.
Adult
Betacoronavirus
COVID-19
China
Coronavirus Infections
/ diagnosis
Cross-Sectional Studies
Female
Health Personnel
Humans
Infection Control
/ instrumentation
Infectious Disease Transmission, Patient-to-Professional
/ prevention & control
Intensive Care Units
Male
Middle Aged
Occupational Exposure
/ prevention & control
Pandemics
/ prevention & control
Personal Protective Equipment
/ supply & distribution
Pneumonia, Viral
/ diagnosis
SARS-CoV-2
Journal
BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488
Informations de publication
Date de publication:
10 06 2020
10 06 2020
Historique:
entrez:
12
6
2020
pubmed:
12
6
2020
medline:
20
6
2020
Statut:
epublish
Résumé
To examine the protective effects of appropriate personal protective equipment for frontline healthcare professionals who provided care for patients with coronavirus disease 2019 (covid-19). Cross sectional study. Four hospitals in Wuhan, China. 420 healthcare professionals (116 doctors and 304 nurses) who were deployed to Wuhan by two affiliated hospitals of Sun Yat-sen University and Nanfang Hospital of Southern Medical University for 6-8 weeks from 24 January to 7 April 2020. These study participants were provided with appropriate personal protective equipment to deliver healthcare to patients admitted to hospital with covid-19 and were involved in aerosol generating procedures. 77 healthcare professionals with no exposure history to covid-19 and 80 patients who had recovered from covid-19 were recruited to verify the accuracy of antibody testing. Covid-19 related symptoms (fever, cough, and dyspnoea) and evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, defined as a positive test for virus specific nucleic acids in nasopharyngeal swabs, or a positive test for IgM or IgG antibodies in the serum samples. The average age of study participants was 35.8 years and 68.1% (286/420) were women. These study participants worked 4-6 hour shifts for an average of 5.4 days a week; they worked an average of 16.2 hours each week in intensive care units. All 420 study participants had direct contact with patients with covid-19 and performed at least one aerosol generating procedure. During the deployment period in Wuhan, none of the study participants reported covid-19 related symptoms. When the participants returned home, they all tested negative for SARS-CoV-2 specific nucleic acids and IgM or IgG antibodies (95% confidence interval 0.0 to 0.7%). Before a safe and effective vaccine becomes available, healthcare professionals remain susceptible to covid-19. Despite being at high risk of exposure, study participants were appropriately protected and did not contract infection or develop protective immunity against SARS-CoV-2. Healthcare systems must give priority to the procurement and distribution of personal protective equipment, and provide adequate training to healthcare professionals in its use.
Identifiants
pubmed: 32522737
doi: 10.1136/bmj.m2195
pmc: PMC7284314
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
m2195Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: grant funding from the First Affiliated Hospital of Sun Yat-sen University; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Références
Influenza Other Respir Viruses. 2011 May;5(3):170-9
pubmed: 21477136
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
JAMA. 2020 Mar 26;:
pubmed: 32215589
J Med Virol. 2020 Apr 22;:
pubmed: 32320064
Front Med. 2020 Apr;14(2):229-231
pubmed: 32212058
Clin Infect Dis. 2020 Mar 17;:
pubmed: 32179890
J Med Virol. 2020 Jul;92(7):903-908
pubmed: 32219885
J Med Virol. 2020 Apr 9;:
pubmed: 32270882
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):477-481
pubmed: 32298247
Lancet Public Health. 2020 May;5(5):e251-e252
pubmed: 32199083
JAMA. 2020 Feb 7;:
pubmed: 32031570
Clin Infect Dis. 2020 Mar 28;:
pubmed: 32221519
Lancet. 2003 May 3;361(9368):1519-20
pubmed: 12737864
Epidemics. 2017 Sep;20:1-20
pubmed: 28487207
J Hosp Infect. 2020 May;105(1):100-101
pubmed: 32147406